Eric Chen

Summary

Publications

  1. Sim H, Nejad R, Zhang W, Nassiri F, Mason W, Aldape K, et al. Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas. Clin Cancer Res. 2019;: pubmed publisher
    ..Finally, rRS values may provide additional prognostic information and further validation is required. ..
  2. Cao Y, Chang Q, Cabanero M, Zhang W, Hafezi Bakhtiari S, Hedley D, et al. Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. J Gastrointest Cancer. 2018;: pubmed publisher
    ..Higher tumor platinum concentration correlated with improved pathological response. Collagen binding potentially explained the high interpatient variability in tumor platinum concentrations. ..
  3. Chen E, Jonker D, Siu L, McKeever K, Keller D, Wells J, et al. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Invest New Drugs. 2016;34:450-7 pubmed publisher
    ..Both olaparib and irinotecan required significant dose reductions. The lack of anti-tumor efficacy observed in this trial makes this combination of little interest for further clinical development. Trial Registration ID NCT00535353. ..
  4. Chiu J, Krzyzanowska M, Serra S, Knox J, Dhani N, MacKay H, et al. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clin Colorectal Cancer. 2018;17:73-79 pubmed publisher
    ..These aberrations may contribute to differential outcomes to anti-epidermal growth factor receptor therapy among patients with right colon, left colon, or rectal cancers. ..